Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | BRAF V600E |
Gene Variant Detail | |
Relevant Treatment Approaches | BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan) |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03668431 | Phase II | Dabrafenib + Spartalizumab + Trametinib | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | Unknown status | USA | 0 |
NCT06758401 | Phase III | Pembrolizumab Pembrolizumab + SGN-B6A | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02) | Not yet recruiting | 0 | |
NCT05026983 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | Recruiting | USA | 0 |
NCT03865082 | Phase II | IMO-2125 + Ipilimumab + Nivolumab | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Active, not recruiting | USA | 0 |
NCT05589818 | Phase II | Pembrolizumab | Pembrolizumab for Advanced NSCLC and PS 2-3 | Recruiting | USA | 0 |
NCT03224767 | Phase II | Cobimetinib + Vemurafenib | Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma | Active, not recruiting | USA | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT04736173 | Phase II | Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10) | Active, not recruiting | USA | TUR | GRC | 9 |
NCT06475989 | Phase III | Dabrafenib + Trametinib Cabozantinib | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Recruiting | USA | 0 |
NCT04619316 | Phase II | Dabrafenib + Trametinib Trametinib | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI) | Recruiting | DEU | 0 |
NCT05694936 | Phase II | Cetuximab + Panitumumab Cetuximab + Panitumumab + Valproic acid | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | Unknown status | AUS | 0 |
NCT02164916 | Phase II | Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib | S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02130466 | Phase Ib/II | Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | Completed | 0 | |
NCT03189030 | Phase I | pLADD | Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT03878719 | Phase I | Binimetinib + Encorafenib | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | Terminated | ITA | 0 |
NCT05270044 | Phase III | Binimetinib + Encorafenib | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD) | Active, not recruiting | SWE | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
NCT05743036 | Phase Ib/II | Cetuximab + Encorafenib + ZN-c3 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | Active, not recruiting | USA | POL | ITA | HUN | ESP | DEU | AUS | 0 |
NCT04061980 | Phase II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT06119581 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium | A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 7 |
NCT02465060 | Phase II | Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Active, not recruiting | USA | 2 |
NCT05223673 | Phase III | Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) | Terminated | USA | HUN | FIN | DNK | BEL | 1 |
NCT05217446 | Phase II | Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) | Active, not recruiting | USA | SWE | SVK | POL | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 0 |
NCT01336634 | Phase II | Dabrafenib Dabrafenib + Trametinib | Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | Completed | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | 3 |
NCT05435846 | Phase I | Capmatinib + Trametinib | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | Terminated | USA | 0 |
NCT05388123 | Phase II | Rituximab + Vemurafenib | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | Recruiting | USA | 0 |
NCT03334617 | Phase II | Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab | Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) | Active, not recruiting | USA | ISR | FRA | ESP | DEU | CAN | AUT | 1 |
NCT03631706 | Phase II | Bintrafusp alfa Pembrolizumab | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 6 |
NCT06578559 | Phase II | Cetuximab + Encorafenib | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET) | Recruiting | ITA | 0 |
NCT04268550 | Phase II | Selpercatinib | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) | Active, not recruiting | USA | 0 |
NCT05097378 | Phase II | Binimetinib + Encorafenib | Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM) | Unknown status | GBR | 0 |
NCT05954871 | Phase I | Cetuximab + GDC-1971 GDC-1971 + Osimertinib | Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer | Active, not recruiting | USA | CAN | AUS | 1 |
NCT06094296 | Phase II | Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Completed | USA | AUS | 0 |
NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | TUR | ISR | GBR | ESP | DNK | 4 |
NCT04034459 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) | Active, not recruiting | DEU | 0 |
NCT05182931 | Phase II | Dabrafenib + Trametinib Trametinib | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST) | Recruiting | AUS | 0 |
NCT04862780 | Phase Ib/II | BLU-945 BLU-945 + Osimertinib | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Terminated | USA | NLD | GBR | FRA | ESP | CAN | 4 |
NCT04083976 | Phase II | Erdafitinib | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 4 |
NCT04995523 | Phase Ib/II | AZD2936 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01) | Recruiting | USA | NLD | GBR | FRA | ESP | DNK | BRA | BEL | AUS | 9 |
NCT05777603 | Phase I | Aztreonam + Pembrolizumab + Vancomycin | Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05241873 | Phase Ib/II | BLU-451 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Terminated | USA | CAN | 3 |
NCT03864042 | Phase I | Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | Completed | USA | NLD | ESP | CAN | BEL | 0 |
NCT04238624 | Phase II | Cemiplimab + Dabrafenib + Trametinib | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | USA | AUS | 0 |
NCT01709292 | Phase II | Vemurafenib | Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT06561386 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093) | Recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 11 |
NCT05788926 | Phase I | TG6050 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Recruiting | FRA | 0 |
NCT05503797 | Phase II | Cobicistat + PLX8394 PLX8394 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT04151563 | Phase Ib/II | Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab | A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy | Withdrawn | USA | ROU | POL | NOR | NLD | GRC | DNK | BEL | ARG | 1 |
NCT06644768 | Phase Ib/II | Pembrolizumab DS-3201b + Pembrolizumab | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Recruiting | USA | BRA | ARG | 3 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT01754376 | Phase II | Aldesleukin + Vemurafenib | Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma | Terminated | USA | 0 |
NCT04418167 | Phase I | JSI-1187 Dabrafenib + JSI-1187 | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | Suspended | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT04171622 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT01638676 | Phase Ib/II | Metformin + Vemurafenib | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | Recruiting | USA | 0 |
NCT01534897 | Phase I | Dabrafenib | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | Completed | USA | 0 |
NCT01943422 | Phase Ib/II | Interferon alpha-2b + Vemurafenib | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | Completed | USA | 0 |
NCT06411600 | Phase II | Bevacizumab + Cetuximab + Encorafenib Bevacizumab | Combination Therapy for BRAF-V600E Metastatic CRCm (BRAVE) | Recruiting | ESP | 0 |
NCT04607421 | Phase III | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | Active, not recruiting | USA | SWE | SVK | POL | NZL | NOR | NLD | ITA | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 9 |
NCT03138889 | Phase Ib/II | NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Terminated | USA | FRA | ESP | DEU | AUS | 0 |
NCT04117945 | Phase II | Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03693170 | Phase II | Binimetinib + Cetuximab + Encorafenib | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) | Completed | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUT | 1 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Active, not recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |
NCT02928224 | Phase III | Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) | Completed | USA | TUR | POL | NOR | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT05480306 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin | Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) | Active, not recruiting | USA | DEU | 1 |
NCT02065063 | Phase I | Palbociclib + Trametinib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | Completed | USA | 0 |
NCT05453799 | Phase II | XmAb20717 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer | Unknown status | USA | 0 |
NCT04551521 | Phase II | Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib | CRAFT: The NCT-PMO-1602 Phase II Trial | Completed | DEU | 0 |
NCT04044430 | Phase Ib/II | Binimetinib + Encorafenib + Nivolumab | Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT03915951 | Phase II | Binimetinib + Encorafenib | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | Active, not recruiting | USA | NLD | ITA | ESP | 1 |
NCT02367859 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma | Completed | USA | 0 |
NCT06625775 | Phase I | BBO-10203 + Trastuzumab BBO-10203 | Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) | Recruiting | USA | AUS | 0 |
NCT05554367 | Phase II | Binimetinib + Palbociclib | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | Recruiting | USA | 1 |
NCT05676749 | Phase I | Aldesleukin + C-TIL051 + Pembrolizumab | C-TIL051 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06074588 | Phase III | Docetaxel SKB264 Pemetrexed Disodium | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Recruiting | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 11 |
NCT01740648 | Phase I | Fluorouracil + Trametinib | Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer | Completed | USA | 0 |
NCT05710406 | Phase II | Cetuximab + Encorafenib | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | Active, not recruiting | USA | 0 |
NCT06784947 | Phase II | Atezolizumab + Bevacizumab + Tiragolumab | A Phase II Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients with Microsatellite Stable, Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT06561360 | Phase II | Cladribine + Rituximab Obinutuzumab + Vemurafenib | A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | Recruiting | USA | 0 |
NCT01750918 | Phase II | Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | Completed | USA | NLD | ITA | GBR | FRA | ESP | BEL | 1 |
NCT05059470 | Phase II | Pembrolizumab | IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC | Active, not recruiting | USA | 0 |
NCT04793815 | FDA approved | Pembrolizumab | Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) | Completed | CAN | 0 |
NCT05650879 | Phase I | ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT05141721 | Phase II | Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03898908 | Phase II | Binimetinib + Encorafenib | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL) | Active, not recruiting | ESP | 0 |
NCT04759846 | Phase I | Binimetinib + Encorafenib | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | Withdrawn | ITA | ESP | CZE | 0 |
NCT01876641 | Phase Ib/II | Decitabine + Vemurafenib | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib | Terminated | USA | 0 |
NCT01726738 | Phase II | Dabrafenib + Trametinib | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | Completed | USA | 0 |
NCT04310397 | Phase II | Dabrafenib + Trametinib Dabrafenib + Spartalizumab + Trametinib | Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | Terminated | USA | 0 |
NCT05308446 | Phase II | Cetuximab + Encorafenib Cetuximab + Encorafenib + Nivolumab | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | Active, not recruiting | USA | 1 |
NCT05564403 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | Suspended | USA | 0 |
NCT04390243 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | Terminated | USA | 0 |
NCT04557956 | Phase Ib/II | Tazemetostat Dabrafenib + Tazemetostat + Trametinib | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | Recruiting | USA | 0 |
NCT05510895 | Phase II | Binimetinib + Cetuximab + Encorafenib | Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF) | Recruiting | DEU | 0 |
NCT05926960 | Phase II | Binimetinib + Encorafenib + Pembrolizumab Ipilimumab + Nivolumab | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE) | Active, not recruiting | SVK | POL | ITA | GBR | ESP | DEU | CZE | 0 |
NCT04581824 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | POL | ITA | FRA | ESP | DEU | BRA | ARG | 3 |
NCT05854498 | Phase II | Bevacizumab + Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT06448572 | Phase Ib/II | EXL01 + Nivolumab | EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. (EXLIBRIS) | Recruiting | FRA | 0 |
NCT02257424 | Phase Ib/II | Dabrafenib + Hydroxychloroquine + Trametinib | Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM) | Completed | USA | 0 |
NCT06495125 | Phase II | Defactinib + Nivolumab + RO5126766 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03255083 | Phase I | DS-1205c + Osimertinib | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Terminated | 1 | |
NCT03244956 | Phase II | Trametinib Dabrafenib + Trametinib | Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) | Unknown status | FRA | 0 |
NCT02949843 | Phase II | Nivolumab + Pembrolizumab | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | Terminated | USA | 0 |
NCT05005273 | Phase II | Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | Completed | USA | TUR | POL | ITA | ISR | FRA | ESP | DEU | BEL | AUS | ARG | 1 |
NCT06364917 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | Not yet recruiting | USA | 0 |
NCT06031688 | Phase II | Tepotinib Ramucirumab + Tepotinib | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT02915666 | Phase I | Dabrafenib + Digoxin + Trametinib | A Clinical Trial of Patients With Melanoma | Withdrawn | USA | 0 |
NCT03839342 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) | Active, not recruiting | CAN | 0 |
NCT04166409 | Phase III | Selumetinib Carboplatin + Vincristine Sulfate | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | Recruiting | USA | CAN | 1 |
NCT03973918 | Phase II | Binimetinib + Encorafenib | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF) | Terminated | USA | 0 |
NCT02143050 | Phase Ib/II | Dabrafenib + Metformin + Trametinib | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | Withdrawn | USA | 0 |
NCT04746924 | Phase III | Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DEU | BRA | AUS | ARG | 8 |
NCT01711632 | Phase II | Vemurafenib | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | Completed | USA | 0 |
NCT03520686 | Phase III | Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. | Active, not recruiting | USA | 0 |
NCT03732703 | Phase Ib/II | Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide | Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) | Completed | USA | 0 |
NCT05706779 | Phase II | Cetuximab + Encorafenib | Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF) | Recruiting | FRA | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT05048797 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | 7 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Completed | USA | SWE | NOR | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 2 |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Recruiting | USA | CAN | 0 |
NCT01897116 | Phase I | Hydroxychloroquine + Vemurafenib | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | Completed | USA | 0 |
NCT03975231 | Phase I | Dabrafenib + Trametinib | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT03803553 | Phase III | Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Recruiting | USA | 0 |
NCT06116682 | Phase II | Amivantamab-vmjw | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT05039177 | Phase Ib/II | Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) | Active, not recruiting | USA | 0 |
NCT04657991 | Phase III | Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Active, not recruiting | USA | TUR | SVK | POL | NZL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | ARG | 4 |
NCT04201457 | Phase Ib/II | Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib | A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | Active, not recruiting | USA | 0 |
NCT06107413 | Phase II | ABBV-400 + Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Recruiting | USA | ISR | ESP | DEU | BEL | 3 |
NCT06532032 | Phase Ib/II | Amivantamab-vmjw + Docetaxel | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail) | Recruiting | USA | TUR | GBR | 1 |
NCT05525273 | Phase II | Dabrafenib + Trametinib | Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma (Swecranio) | Recruiting | SWE | 0 |
NCT04787341 | Phase II | Regorafenib Panitumumab | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) | Active, not recruiting | ITA | 0 |
NCT05852223 | Phase II | Pembrolizumab | Pembrolizumab in High-risk Thyroid Cancer (NePenThe) | Not yet recruiting | ITA | 0 |
NCT03840915 | Phase Ib/II | Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | Completed | USA | FRA | BEL | 0 |
NCT04252339 | Phase I | GDC-1971 | RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT04534283 | Phase II | Abemaciclib + LY3214996 | A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | Terminated | USA | 0 |
NCT06610682 | Phase I | PLX8394 | Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib | Not yet recruiting | USA | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT05576896 | Phase II | Encorafenib + Hydroxychloroquine + Panitumumab Cetuximab + Encorafenib + Hydroxychloroquine | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | Recruiting | USA | 0 |
NCT04126733 | Phase II | Nivolumab + Regorafenib | Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) | Completed | USA | 0 |
NCT03235245 | Phase II | Binimetinib + Encorafenib Ipilimumab + Nivolumab | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) | Active, not recruiting | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | 0 |
NCT03608046 | Phase II | Avelumab + Cetuximab + Irinotecan | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI) | Unknown status | BEL | 0 |
NCT06440850 | Phase II | Cobimetinib + Vemurafenib | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | Recruiting | USA | 0 |
NCT05462613 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02) | Recruiting | FRA | 0 |
NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04074096 | Phase II | Binimetinib + Encorafenib + Pembrolizumab | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) | Active, not recruiting | FRA | 0 |
NCT04675710 | Phase II | Dabrafenib + Pembrolizumab + Trametinib | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04017650 | Phase Ib/II | Cetuximab + Encorafenib + Nivolumab | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT06194929 | Phase Ib/II | Defactinib + Encorafenib + RO5126766 Defactinib + RO5126766 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) | Recruiting | USA | 0 |
NCT05364645 | Phase II | Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT06369259 | Phase II | Cetuximab + Defactinib + RO5126766 | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | Recruiting | USA | 0 |
NCT05985954 | Phase I | Cetuximab + Encorafenib + Ulixertinib Cetuximab + Ulixertinib | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | Recruiting | USA | 0 |
NCT01748149 | Phase I | Vemurafenib | Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas | Active, not recruiting | USA | CAN | 0 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04585815 | Phase Ib/II | Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | Terminated | USA | GBR | BEL | AUS | 1 |
NCT06102902 | Phase I | Cetuximab + Encorafenib + ZEN-3694 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | Recruiting | USA | 0 |
NCT04526782 | Phase II | Docetaxel Binimetinib + Encorafenib | ENCOrafenib with Binimetinib in BRAF NSCLC (ENCO-BRAF) | Active, not recruiting | FRA | 0 |
NCT01721603 | Phase II | Dabrafenib | A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases | Terminated | USA | 0 |
NCT01659151 | Phase II | Aldesleukin Fludarabine Vemurafenib | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT05469178 | Phase Ib/II | Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer | Recruiting | USA | POL | ITA | HUN | GRC | FRA | ESP | 0 |
NCT06640166 | Phase II | Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin | Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse) | Recruiting | ITA | 0 |
NCT05330429 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05153408 | Phase Ib/II | BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Terminated | USA | 0 |
NCT04623775 | Phase II | Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 3 |
NCT05203172 | FDA approved | Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Recruiting | USA | SVK | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 4 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | NZL | FRA | ESP | DNK | 1 |
NCT03475004 | Phase II | Bevacizumab + Binimetinib + Pembrolizumab | Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | Completed | USA | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT03365882 | Phase II | Cetuximab + Irinotecan Pertuzumab + Trastuzumab | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 1 |
NCT01089101 | Phase Ib/II | Selumetinib | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | Active, not recruiting | USA | 0 |